1780-32-1Relevant articles and documents
Indole pyrimidine compound as well as synthesis method and application thereof
-
Paragraph 0062-0064, (2021/07/21)
The invention discloses an indole pyrimidine compound, the structural formula of which is as shown in formula (I): wherein L is selected from any one of H, OH, halogen, alkoxy, halogenated alkyl, alkyl, aryl and pyridine, Q is O, S or NH, X is NH or -CONH, n is a natural number, R is N(CH3)2 or T is selected from at least one of H, OH, halogen, alkoxy, halogenated alkyl, alkyl, aryl and pyridine. The indole pyrimidine compound provided by the invention can effectively inhibit adipocyte differentiation, and has a better lipid-lowering effect.
BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
-
Page/Page column 253, (2017/05/02)
Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
MONO AND BICYCLIC RING BORONIC ACID, ESTER AND SALT COMPOUNDS AS INHIBITORS OF P97 COMPLEX
-
Page/Page column 414, (2016/12/26)
Monocyclic or bicyclic ring boronic acid or ester compounds having an arylalkyi amine substituent at the 4 position and a substituted 5:6 bicyclic group at the 2 position of the mono or bicyclic ring boronic acid or ester as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the mono or bicyclic boronic acid or ester compounds are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with the Valosin containing protein and p97 bioactivity such as cancer. Formula (I).